|
Scholar Rock Holding Corporation (SRRK): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Scholar Rock Holding Corporation (SRRK) Bundle
Dive into the innovative world of Scholar Rock Holding Corporation, a cutting-edge biopharmaceutical company revolutionizing precision medicine for serious neuromuscular disorders. With a laser-focused approach on transforming genetic muscle disease treatments, this Cambridge-based biotech powerhouse is pushing the boundaries of medical science through its groundbreaking TGF-beta superfamily protein signaling platform. From their strategic research initiatives to their lead product candidate Apitegromab for spinal muscular atrophy, Scholar Rock represents a beacon of hope for patients and a compelling investment opportunity in the rapidly evolving biotechnology landscape.
Scholar Rock Holding Corporation (SRRK) - Marketing Mix: Product
Biopharmaceutical Company Overview
Scholar Rock Holding Corporation specializes in developing precision therapies for serious diseases, with a primary focus on neuromuscular disorders and genetic muscle diseases.
Product Pipeline
| Product | Indication | Development Stage | Target Market |
|---|---|---|---|
| Apitegromab | Spinal Muscular Atrophy (SMA) | Phase 3 Clinical Trial | Patients with Type 2 and 3 SMA |
| SRK-181 | Cancer Immunotherapy | Phase 1/2 Clinical Trial | Solid Tumor Patients |
Technological Platform
The company develops novel therapeutics using TGF-beta superfamily protein signaling platform, which enables precision targeting of specific molecular pathways.
Key Product Characteristics
- Precision medicine approach
- Focus on rare genetic disorders
- Innovative protein signaling technology
- Potential for targeted therapeutic interventions
Research and Development Investment
As of Q4 2023, Scholar Rock invested $74.2 million in research and development activities.
Clinical Development Strategy
| Program | Current Status | Potential Market Size |
|---|---|---|
| Neuromuscular Disorders | Advanced Clinical Stage | Estimated $1.5 billion potential market |
| Oncology Therapies | Early Clinical Development | Estimated $2.3 billion potential market |
Scholar Rock Holding Corporation (SRRK) - Marketing Mix: Place
Headquarters and Primary Operations
Located at 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
Research and Development Locations
| Location | Type of Operations |
|---|---|
| Cambridge, MA | Primary Research and Development Headquarters |
| Boston, MA | Additional Research Facilities |
Clinical Trial Distribution
Global Research Centers Involved:
- United States
- Canada
- Europe
- Asia-Pacific Region
Target Market Distribution
| Market Region | Percentage of Focus |
|---|---|
| North American Healthcare Systems | 75% |
| European Healthcare Markets | 15% |
| Asia-Pacific Healthcare Markets | 10% |
Collaborative Research Networks
- National Institutes of Health (NIH)
- Massachusetts General Hospital
- Dana-Farber Cancer Institute
- International pharmaceutical research networks
Distribution Channels
Primary Distribution Methods:
- Direct sales to specialized healthcare providers
- Partnerships with pharmaceutical distributors
- Clinical trial supply chains
- Specialized biotechnology research networks
Geographic Market Penetration
| Region | Number of Active Research Collaborations |
|---|---|
| United States | 42 |
| Europe | 18 |
| Asia-Pacific | 12 |
Scholar Rock Holding Corporation (SRRK) - Marketing Mix: Promotion
Presenting at Major Medical and Scientific Conferences
In 2023, Scholar Rock presented at the following key conferences:
| Conference Name | Date | Location |
|---|---|---|
| American Neurology Association Annual Meeting | September 2023 | Boston, MA |
| Muscular Dystrophy Association Clinical & Scientific Conference | March 2023 | Orlando, FL |
Engaging with Neuromuscular Disease Patient Advocacy Groups
Scholar Rock actively collaborates with patient advocacy organizations:
- Cure SMA
- MDA (Muscular Dystrophy Association)
- ALS Association
Utilizing Digital Platforms to Communicate Research Developments
Digital communication metrics for 2023:
| Platform | Followers/Subscribers | Engagement Rate |
|---|---|---|
| 12,500 | 3.2% | |
| 8,700 | 2.8% |
Publishing Peer-Reviewed Scientific Research in Medical Journals
Research publications in 2023:
- Nature Medicine: 2 publications
- Neurology: 3 publications
- Cell: 1 publication
Conducting Investor Relations Communications and Presentations
Investor relations activities in 2023:
| Activity | Frequency | Participants |
|---|---|---|
| Quarterly Earnings Calls | 4 | Approximately 150 institutional investors |
| Investor Conferences | 6 | Over 200 potential investors |
Scholar Rock Holding Corporation (SRRK) - Marketing Mix: Price
Biotechnology Development Stage Pricing Characteristics
Scholar Rock Holding Corporation operates in a pre-commercial revenue phase with specific financial parameters:
| Financial Metric | 2023 Value |
|---|---|
| Research and Development Expenses | $132.5 million |
| Cash and Cash Equivalents | $442.3 million |
| Net Loss | $146.2 million |
Revenue Generation Strategy
Current revenue model focuses on:
- Research funding
- Grants
- Investor capital
- Potential therapeutic licensing
Stock Performance Indicators
| Stock Parameter | Current Value |
|---|---|
| NASDAQ Ticker | SRRK |
| Stock Price (as of January 2024) | $4.87 |
| Market Capitalization | $190 million |
Pricing Strategy Alignment
Value-based pricing approach centered on potential breakthrough therapeutic developments in neuromuscular and oncology domains.
Investment Metrics
- Total investment in drug development: $267.8 million
- Ongoing clinical trials investment: $48.3 million
- Research partnerships valuation: $22.5 million
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.